![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Argent Biopharma Limited | LSE:RGT | London | Ordinary Share | AU0000326647 | ORD NPV (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.00 | 5.00 | 7.00 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMRGT 1 February 2011 ReGen Therapeutics Plc ("ReGen" or the "Company") Amendment to Timetable ReGen announces an amendment to the timetable included in the circular sent to shareholders on 12 January 2011 and repeated in the Result of General Meeting announcement issued on 28 January 2011. The amendments are as follows: * The original "Last day of dealings" line has been reworded to clarify that this date refers exclusively to the last day of dealings in ReGen Ordinary Shares on AIM to allow entry on the Shareholder register prior to the Record Time. This date has been amended from 10 February 2011 to 9 February 2011 to allow for a T+3 settlement period. * An additional line has been included below to clarify that the last day of dealings in ReGen Ordinary Shares cum entitlement to participate in the Demerger is 17 February 2011; and * A further additional line has been included below to clarify that 18 February 2011 will be the first day on which ReGen Ordinary Shares will begin trading ex entitlement to participate in the Demerger (under the new name of Alexander David Investments PLC). The full revised timetable of future significant events relating to the Demerger is therefore as follows: Last day of dealings (with a T+3 settlement) in 9 February 2011 ReGen Ordinary Shares on AIM to allow entry on the Shareholder register prior to the Record Time Record Time for the purposes of determining the 6.00 p.m. on 14 February 2011 Shareholders entitled to participate in the Demerger and the grant of New Warrants Bonus Issue 15 February 2011 Court Hearing to confirm Reduction of Capital 16 February 2011 Reduction of Capital becomes effective 17 February 2011 Last day of dealings in ReGen Ordinary Shares on 17 February 2011 AIM cum entitlement to participate in Demerger Expected date of the Demerger 18 February 2011 Change of name of ReGen Therapeutics Plc to 18 February 2011 Alexander David Investments PLC ReGen Ordinary Shares begin trading under the new 18 February 2011 name of Alexander David Investments PLC (AIM: ADI) ex entitlement to participate in the Demerger CREST accounts credited with NewCo Shares 18 February 2011 Posting of share certificates for the NewCo Shares By 8 March 2011 to certificated Shareholders Posting of warrant certificates for the New By 8 March 2011 Warrants to Shareholders Definitions of all defined terms referred to above are available in the circular sent to shareholders on 12 January 2011, which is available at the Company's website at www.regentherapeutics.com. Enquiries: ReGen Therapeutics Plc +44 20 7153 4920 Percy Lomax Cairn Financial Advisers LLP +44 20 7148 7900 Nominated Adviser Liam Murray / Avi Robinson Alexander David Securities Limited +44 20 7448 9820 Broker David Scott / Nick Bealer This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: ReGen Therapeutics Plc via Thomson Reuters ONE [HUG#1484403]
1 Year Argent Biopharma Chart |
1 Month Argent Biopharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions